Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases

Purpose Some metastatic colorectal cancer (mCRC) patients receive conversion surgery (CS), including metastasectomy after palliative chemotherapy. Although targeted agents significantly improved the outcomes, the clinical outcome of CS in the targeted agent era has not yet been thoroughly investigat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cancer research and clinical oncology 2020-09, Vol.146 (9), p.2399-2410
Hauptverfasser:	Kim, Sang-A, Kim, Ji-Won, Suh, Koung Jin, Chang, Won, Kim, Jin Won, Oh, Heung-Kwon, Cho, Jai Young, Kim, Duck-Woo, Cho, Sukki, Kim, Jee Hyun, Kim, Kwhanmien, Kang, Sung-Bum, Jheon, Sanghoon, Lee, Keun-Wook
Format:	Artikel
Sprache:	eng
Schlagworte:	Bevacizumab Cancer Research Chemotherapy Colorectal cancer Colorectal carcinoma Hematology Immunotherapy Internal Medicine Liver Liver cancer Medicine Medicine & Public Health Metastases Metastasis Monoclonal antibodies Oncology Original Article – Clinical Oncology Patients Surgery Survival Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!